Filing Details
- Accession Number:
- 0001387131-23-001468
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-06 16:18:12
- Reporting Period:
- 2021-08-12
- Accepted Time:
- 2023-02-06 16:18:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1570562 | Evolus Inc. | EOLS | Pharmaceutical Preparations (2834) | 461385614 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1848514 | Medytox Inc. | 78, Gangni 1-Gil, Ochang-Eup, Cheongwon-Gu Cheogiu-Si M5 28126 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $0.00001 Par Value Per Share | Acquisiton | 2021-08-12 | 23,000 | $10.99 | 7,282,500 | No | 4 | P | Indirect | See Footnote |
Common Stock, $0.00001 Par Value Per Share | Acquisiton | 2021-08-13 | 14,043 | $11.11 | 7,296,543 | No | 4 | P | Indirect | See Footnote |
Common Stock, $0.00001 Par Value Per Share | Disposition | 2023-01-20 | 37,043 | $11.04 | 7,259,500 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- Inadvertently filed late due to an administrative error.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive.
- The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership.